Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder
Published December 15, 2020
Output Details
Published December 15, 2020
Description
Individuals with idiopathic rapid eye movement sleep behavior disorder (iRBD) are at high risk for a clinical diagnosis of an α‐synucleinopathy (aSN). They could serve as a key population for disease‐modifying trials. Abnormal dopamine transporter (DAT) imaging is a strong candidate biomarker for risk of aSN diagnosis in iRBD. Our primary objective was to identify a quantitative measure of DAT imaging that predicts diagnosis of clinically‐defined aSN in iRBD.
Identifier (DOI)
10.1002/acn3.51269
